OSCIENT PHARMACEUTICALS CORPORATION ANNOUNCES RESULTS OF FDA ADVISORY COMMITTEE MEETING FOR FACTIVE TABLETS FOR THE TREATMENT OF ACUTE BACTERIAL SINUSITIS

Oscient Pharmaceuticals has announced the results of a meeting of the U.S. Food and Drug Administration's (FDA) Anti-Infective Drugs Advisory Committee. The panel voted on topics related to the Company's pending supplemental New Drug Application (sNDA) seeking approval for the use of FACTIVE (gemifloxacin mesylate) tablets in treating acute bacterial sinusitis (ABS).
BioSpace